RecruitingPhase 2

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

United States25 participantsStarted 2025-03-05

Plain-language summary

This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕-Women of childbearing potential (WoCBP) may be included only if acceptable contraception (see Appendix C) is in place for two weeks before study entry, for the duration of the treatment with the study drug and for 5x half-lives of ZN-c3 + 6 months after the last dose of ZN-c3. Sexually active female subjects of childbearing potential must agree to use protocol-recommended method of contraception from the start of the screening period until 6 months after the last dose of study drug ZN-c3.

What they're measuring

Percentage Change in Replication Fork Speed in Overall Response

Timeframe: Up to 7 months

Percentage Change in Replication Fork Speed in 6 Month Progression Free Survival (PFS6)

Timeframe: At 6 months

Trial details

NCT IDNCT06369155

SponsorJoyce Liu, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01-31

Contact for this trial

Joyce Liu, MD, MPH

617-632-5269 Joyce_Liu@DFCI.HARVARD.EDU

View on ClinicalTrials.gov More Uterine Serous Carcinoma trials